Pharmafile Logo

conjoint

Case study

Using qualitative conjoint to assess willingness-to-pay

Research Partnership

- PMLiVE

Novavax plans to meet US COVID-19 vaccine demand in 2021

Company plans to produce two billion doses if vaccine proves effective

Article: Pricing a coronavirus vaccine

Using findings from Research Partnership's recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read...

Research Partnership

- PMLiVE

Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Alleged deal could include agreement for 60 million doses

- PMLiVE

AMICULUM® launches new specialist agency: AMICULUM Access

AMICULUM Access is a full-service market access agency bringing together existing in-house market access expertise from across AMICULUM’s agencies to provide a consolidated service to both new and existing clients.

AMICULUM

- PMLiVE

Did Trump offer CureVac $1bn for COVID-19 vaccine rights?

Media reports claim Trump administration tried to secure exclusive rights

- PMLiVE

UK confirms first cases of coronavirus as global concerns mount

Pharma industry steps up its efforts to develop therapeutics for infection

- PMLiVE

GSK licenses its tuberculosis vaccine to Gates MRI

Vaccine has demonstrated around 50% efficacy in preventing disease

- PMLiVE

OPEN Health expands global footprint with Pharmerit International integration

Global health comms and market access group now has presence in six countries

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

Genital herpes vaccine candidate heads for human studies

Follows decades of failed R&D into sexually-transmitted infection

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links